Serum ACE2 and S19P gene polymorphism in Egyptian patients with COVID-19 infection: correlation with disease severity

The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 pati...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 14; no. 1; pp. 5846 - 13
Main Authors Gaber, Dalia A., Shokr, Mohamed, Shaker, Olfat, Zaki, Kamelia Ahmed, Khalil, Haidy Samir, Wahb, Amany M.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 10.03.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients ( p =  0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls ( p -value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients ( p <  0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p <  0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.
AbstractList The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients (p = 0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls (p-value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients (p < 0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p < 0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.
The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients ( p =  0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls ( p -value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients ( p <  0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p <  0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.
Abstract The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients (p = 0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls (p-value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients (p < 0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p < 0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.
The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients (p = 0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls (p-value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients (p < 0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p < 0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2 infection and its outcome. In our study, serum ACE2 and its genetic variant S19P rs73635825 polymorphism were investigated in 114 SARS-CoV-2 patients. The results were compared with 120 control subjects. ELISA technique and allele discrimination assay were used for measuring serum ACE2 and genotype analysis of ACE2 rs73635825. Our results revealed that serum ACE2 was significantly lower in SARS-CoV-2 patients (p = 0.0001), particularly in cases with hypertension or diabetes mellitus. There was a significant difference in the genotype distributions of ACE2 rs73635825 A > G between COVID-19 patients and controls (p-value = 0.001). A higher frequency of the heterozygous AG genotype (65.8%) was reported in COVID-19 patients. The G allele was significantly more common in COVID-19 patients (p < 0.0001). The AG and GG genotypes were associated with COVID-19 severity as they were correlated with abnormal laboratory findings, GGO, CXR, and total severity scores with p < 0.05. Our results revealed that the ACE2 S19P gene variant is correlated with the incidence of infection and its severity, suggesting the usefulness of this work in identifying the susceptible population groups for better disease control.
ArticleNumber 5846
Author Wahb, Amany M.
Zaki, Kamelia Ahmed
Shokr, Mohamed
Shaker, Olfat
Gaber, Dalia A.
Khalil, Haidy Samir
Author_xml – sequence: 1
  givenname: Dalia A.
  orcidid: 0000-0003-2676-9152
  surname: Gaber
  fullname: Gaber, Dalia A.
  email: dalia.ali@med.helwan.edu.eg, dr.dalia@gmu.ac.ae
  organization: Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Helwan University, College of Medicine, Gulf Medical University
– sequence: 2
  givenname: Mohamed
  orcidid: 0009-0008-6805-4810
  surname: Shokr
  fullname: Shokr, Mohamed
  organization: Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, MUST University
– sequence: 3
  givenname: Olfat
  orcidid: 0000-0002-3031-3599
  surname: Shaker
  fullname: Shaker, Olfat
  organization: Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University
– sequence: 4
  givenname: Kamelia Ahmed
  surname: Zaki
  fullname: Zaki, Kamelia Ahmed
  organization: Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, MUST University
– sequence: 5
  givenname: Haidy Samir
  surname: Khalil
  fullname: Khalil, Haidy Samir
  organization: Medical Microbiology and Immunology, Faculty of Medicine, Helwan University
– sequence: 6
  givenname: Amany M.
  orcidid: 0000-0001-7063-4285
  surname: Wahb
  fullname: Wahb, Amany M.
  organization: Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Helwan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38462662$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_0D7BAltiwCfiZ2GxQNUxhpEpFKrC1nOQm41FiBzspmn-PpymlZYEly4985_jq5pxmR847yLJXBL8jmMn3kROhZI4pz0VBC5wXz7ITirnIKaP06NH-ODuPcYfTEFRxol5kx0zypCnoSTbfQJgHdLFaU2Rcg26I-oo6cIBG3-8HH8atjQOyDq27_ThZ49BoJgtuiuiXnbZodf1j8yknKiEt1JP17gOqfQjQm8NhgRobwURAEW4h2Gn_Mnvemj7C-f16ln2_XH9bfcmvrj9vVhdXec0VnXLguKFt24JkFCRg3IAxjChVybKkRggBDeMM0pRYtJXEpFCmxgZkWRnF2Fm2WXwbb3Z6DHYwYa-9sfruwodOmzDZugfdlBVnnOCSqYqn1lS8LTFXhZACKLRN8vq4eI1zNUBTpxYE0z8xffrF2a3u_K0mWFEhpEwOb-8dgv85Q5z0YGMNfW8c-DlqqoSgheRYJPTNP-jOz8GlXh0oXohUKE_U68clPdTy5_cmgC5AHXyMAdoHhGB9iJFeYqRTjPRdjHSRRGwRxQS7DsLft_-j-g10qcjA
Cites_doi 10.3389/fped.2020.00206
10.3390/ijms21103474
10.3390/jpm11111098
10.3390/genes11070741
10.1016/j.gene.2020.145102
10.3390/v13010067
10.1002/ddr.21656
10.3389/fgene.2022.888025
10.1016/j.ejim.2020.04.037
10.1097/FPC.0000000000000436
10.2147/IJGM.S310577
10.1093/ehjcvp/pvaa053
10.2174/1871526520666200518073329
10.3389/fmed.2020.00335
10.1002/mgg3.1344
10.1016/j.jmii.2020.04.015
10.1111/acel.13168
10.1016/j.phrs.2020.104833
10.3390/v14071451
10.3390/ijerph17103433
10.1016/S0140-6736(20)30211-7
10.3389/fmed.2020.563893
10.1371/journal.pone.0252799
10.1148/radiol.2020201473
10.1016/j.expneurol.2021.113837
10.1148/ryct.2020200213
10.1186/s12985-022-01782-6
10.1183/13993003.01112-2020
10.1016/j.vph.2021.106934
10.1001/jamacardio.2020.1282
10.1139/gen-2020-0124
10.1186/s13054-020-03120-0
10.3389/fcimb.2021
10.1016/j.cell.2023.01.039
10.3760/cma.j.issn.1001-0939.2020.03.016
10.1161/01.res.87.5.e1
10.17219/acem/163409
10.1016/j.cca.2020.08.019
10.1016/j.lfs.2020.117905
10.1016/j.genrep.2020.100979
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-024-56260-6
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
CrossRef


Publicly Available Content Database
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 13
ExternalDocumentID oai_doaj_org_article_d7b43410739b4662b4f70496585e2efd
PMC10925588
38462662
10_1038_s41598_024_56260_6
Genre Journal Article
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
NPM
7XB
8FK
AARCD
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c492t-e40d2fffe832e8e00deaa3199b8772a555ed343e343805fb80169ac0ae87ba933
IEDL.DBID 7X7
ISSN 2045-2322
IngestDate Wed Aug 27 01:26:15 EDT 2025
Thu Aug 21 18:34:44 EDT 2025
Fri Jul 11 08:30:41 EDT 2025
Wed Aug 13 09:11:59 EDT 2025
Thu Apr 03 07:04:38 EDT 2025
Tue Jul 01 00:51:34 EDT 2025
Fri Feb 21 02:37:51 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c492t-e40d2fffe832e8e00deaa3199b8772a555ed343e343805fb80169ac0ae87ba933
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2676-9152
0000-0001-7063-4285
0009-0008-6805-4810
0000-0002-3031-3599
OpenAccessLink https://www.proquest.com/docview/2954651074?pq-origsite=%requestingapplication%
PMID 38462662
PQID 2954651074
PQPubID 2041939
PageCount 13
ParticipantIDs doaj_primary_oai_doaj_org_article_d7b43410739b4662b4f70496585e2efd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10925588
proquest_miscellaneous_2955268405
proquest_journals_2954651074
pubmed_primary_38462662
crossref_primary_10_1038_s41598_024_56260_6
springer_journals_10_1038_s41598_024_56260_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-10
PublicationDateYYYYMMDD 2024-03-10
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-10
  day: 10
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Hernández (CR35) 2021; 345
Möhlendick (CR16) 2021; 31
Vadgama (CR25) 2020; 13
Fan, Lu, Li, Ding, Wang (CR34) 2021; 7
Pagliaro, Penna (CR5) 2020; 7
Khothari (CR44) 2004
Ciaglia, Vecchione, Puca (CR28) 2020; 8
de Jaegere, Krdzalic, Fasen, Kwee (CR23) 2020; 2
Gómez (CR41) 2020; 762
Strafella, Caputo, Termine, Barati, Gambardella, Borgiani, Caltagirone, Novelli, Giardina, Cascella (CR36) 2020; 11
Devaux, Rolain, Raoult (CR14) 2020; 53
Pourbagheri-Sigaroodi, Bashash, Fateh, Abolghasemi (CR33) 2020; 510
Beacon, Delcuve, Davie (CR13) 2021; 64
Sun, Yang, Sun, Su (CR7) 2020; 43
Ni (CR12) 2020; 24
Banu, Panikar, Leal, Leal (CR3) 2020; 256
Bavishi, Maddox, Messerli (CR1) 2020; 5
Mir (CR43) 2021; 11
Oudit (CR27) 2023; 186
Setiawati (CR24) 2021; 9
Ciaglia, Vecchione, Puca (CR8) 2020; 8
Li, Cao, Rahman (CR20) 2020; 8
Annweiler (CR6) 2020; 20
Paniri, Hosseini, Moballegh-Eslam, Akhavan-Niaki (CR19) 2021; 22
Gurwitz (CR9) 2020; 81
Alimoradi (CR15) 2022; 19
Darbani (CR18) 2020; 17
Donoghue (CR2) 2000; 87
Offringa (CR10) 2020; 6
Liu (CR32) 2020; 55
Akbari (CR39) 2022; 142
Chen (CR29) 2020; 395
Chen (CR40) 2021; 11
Hu, Bauer, Sawyer, Diaz-Griffero (CR21) 2022; 14
Hashizume (CR26) 2021; 13
Prokop (CR22) 2020; 296
Tug (CR31) 2023
Möhlendick (CR42) 2021; 31
Gemmati (CR17) 2020; 21
Kragstrup (CR38) 2021; 16
Li, Zhou, Yang, You (CR4) 2020; 157
Chen (CR37) 2020; 19
Verdecchia, Cavallini, Spanevello, Angeli (CR11) 2020; 76
Alimoradi, Sharqi, Firouzabadi, Sadeghi, Moezzi (CR30) 2022; 19
CR Khothari (56260_CR44) 2004
J Chen (56260_CR37) 2020; 19
A Paniri (56260_CR19) 2021; 22
R Setiawati (56260_CR24) 2021; 9
M Donoghue (56260_CR2) 2000; 87
CA Devaux (56260_CR14) 2020; 53
N Banu (56260_CR3) 2020; 256
A Pourbagheri-Sigaroodi (56260_CR33) 2020; 510
C Fan (56260_CR34) 2021; 7
GY Oudit (56260_CR27) 2023; 186
D Gurwitz (56260_CR9) 2020; 81
P Pagliaro (56260_CR5) 2020; 7
Y Liu (56260_CR32) 2020; 55
M Mir (56260_CR43) 2021; 11
B Möhlendick (56260_CR42) 2021; 31
E Ciaglia (56260_CR28) 2020; 8
C Annweiler (56260_CR6) 2020; 20
C Bavishi (56260_CR1) 2020; 5
E Tug (56260_CR31) 2023
P Hu (56260_CR21) 2022; 14
E Ciaglia (56260_CR8) 2020; 8
W Ni (56260_CR12) 2020; 24
ML Sun (56260_CR7) 2020; 43
B Darbani (56260_CR18) 2020; 17
M Akbari (56260_CR39) 2022; 142
A Offringa (56260_CR10) 2020; 6
B Möhlendick (56260_CR16) 2021; 31
TMH de Jaegere (56260_CR23) 2020; 2
N Alimoradi (56260_CR15) 2022; 19
C Strafella (56260_CR36) 2020; 11
TW Kragstrup (56260_CR38) 2021; 16
N Alimoradi (56260_CR30) 2022; 19
Y Li (56260_CR4) 2020; 157
D Gemmati (56260_CR17) 2020; 21
J Gómez (56260_CR41) 2020; 762
TH Beacon (56260_CR13) 2021; 64
Q Li (56260_CR20) 2020; 8
N Chen (56260_CR29) 2020; 395
M Hashizume (56260_CR26) 2021; 13
N Vadgama (56260_CR25) 2020; 13
F Chen (56260_CR40) 2021; 11
VS Hernández (56260_CR35) 2021; 345
P Verdecchia (56260_CR11) 2020; 76
M Prokop (56260_CR22) 2020; 296
References_xml – volume: 8
  start-page: 206
  year: 2020
  ident: CR8
  article-title: COVID-19 infection and circulating ACE2 levels: Protective role in women and children
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2020.00206
– volume: 21
  start-page: 3474
  issue: 10
  year: 2020
  ident: CR17
  article-title: COVID-19 and individual genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males?
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21103474
– volume: 11
  start-page: 1098
  issue: 11
  year: 2021
  ident: CR43
  article-title: Strong association of angiotensin converting enzyme-2 gene insertion/deletion polymorphism with susceptibility to SARS-CoV-2, hypertension, coronary artery disease and COVID-19 disease mortality
  publication-title: J. Pers. Med.
  doi: 10.3390/jpm11111098
– volume: 11
  start-page: 741
  issue: 7
  year: 2020
  ident: CR36
  article-title: Analysis of genetic variability among populations highlights a possible link with COVID-19-related neurological complications
  publication-title: Genes
  doi: 10.3390/genes11070741
– volume: 762
  start-page: 145102
  year: 2020
  ident: CR41
  article-title: Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
  publication-title: Gene
  doi: 10.1016/j.gene.2020.145102
– volume: 13
  start-page: 67
  issue: 1
  year: 2021
  ident: CR26
  article-title: Population-specific single-nucleotide polymorphisms have limited impact on SARS-CoV-2 infectivity in vitro
  publication-title: Viruses
  doi: 10.3390/v13010067
– volume: 81
  start-page: 537
  year: 2020
  end-page: 540
  ident: CR9
  article-title: Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
  publication-title: Drug Dev. Res.
  doi: 10.1002/ddr.21656
– volume: 13
  start-page: 888025
  year: 2020
  ident: CR25
  article-title: SARS-CoV-2 susceptibility and ACE2 gene variations within diverse ethnic backgrounds
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2022.888025
– volume: 76
  start-page: 14
  year: 2020
  end-page: 20
  ident: CR11
  article-title: The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
  publication-title: Eur. J. Intern. Med.
  doi: 10.1016/j.ejim.2020.04.037
– volume: 31
  start-page: 165
  issue: 8
  year: 2021
  end-page: 171
  ident: CR42
  article-title: ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/FPC.0000000000000436
– volume: 9
  start-page: 2407
  issue: 14
  year: 2021
  end-page: 2412
  ident: CR24
  article-title: Modified chest X-ray scoring system in evaluating severity of COVID-19 patient in Dr. Soetomo General Hospital Surabaya, Indonesia
  publication-title: Int. J. Gen. Med.
  doi: 10.2147/IJGM.S310577
– volume: 6
  start-page: 317
  year: 2020
  end-page: 325
  ident: CR10
  article-title: The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: Possible treatment options related to the renin-angiotensin system
  publication-title: Eur. Heart J. Cardiovasc. Pharmacother.
  doi: 10.1093/ehjcvp/pvaa053
– volume: 20
  start-page: 407
  year: 2020
  end-page: 408
  ident: CR6
  article-title: Counter-regulatory ‘Renin-Angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients
  publication-title: Infect. Disord. Drug Targets.
  doi: 10.2174/1871526520666200518073329
– volume: 7
  start-page: 335
  year: 2020
  ident: CR5
  article-title: ACE/ACE2 ratio: A key also in 2019 coronavirus disease (Covid-19)?
  publication-title: Front. Med.
  doi: 10.3389/fmed.2020.00335
– volume: 8
  start-page: e1344
  year: 2020
  ident: CR20
  article-title: Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations
  publication-title: Mol. Genet. Genom. Med.
  doi: 10.1002/mgg3.1344
– volume: 53
  start-page: 425
  issue: 3
  year: 2020
  end-page: 435
  ident: CR14
  article-title: ACE2 receptor polymorphism: Susceptibility to SARS CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
  publication-title: J. Microbiol. Immunol. Infect.
  doi: 10.1016/j.jmii.2020.04.015
– volume: 19
  start-page: e13168
  issue: 7
  year: 2020
  ident: CR37
  article-title: Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation
  publication-title: Aging Cell.
  doi: 10.1111/acel.13168
– volume: 157
  start-page: 104833
  year: 2020
  ident: CR4
  article-title: Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2020.104833
– volume: 14
  start-page: 1451
  issue: 7
  year: 2022
  ident: CR21
  article-title: Human ACE2 polymorphisms from different human populations modulate SARS-CoV-2 infection
  publication-title: Viruses.
  doi: 10.3390/v14071451
– volume: 17
  start-page: 3433
  issue: 10
  year: 2020
  ident: CR18
  article-title: The expression and polymorphism of entry machinery for COVID-19 in human: Juxtaposing population groups, gender, and different tissues
  publication-title: Int. J. Environ. Res. Public Health.
  doi: 10.3390/ijerph17103433
– volume: 395
  start-page: 507
  year: 2020
  end-page: 513
  ident: CR29
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 7
  start-page: 563893
  year: 2021
  ident: CR34
  article-title: ACE2 Expression in kidney and testis may cause kidney and testis infection in COVID-19 patients
  publication-title: Front Med
  doi: 10.3389/fmed.2020.563893
– volume: 16
  start-page: e0252799
  issue: 6
  year: 2021
  ident: CR38
  article-title: Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients
  publication-title: PLoS ONE.
  doi: 10.1371/journal.pone.0252799
– volume: 296
  start-page: E97
  issue: 2
  year: 2020
  end-page: E104
  ident: CR22
  article-title: COVID-19 standardized reporting working group of the Dutch radiological society. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation
  publication-title: Radiology.
  doi: 10.1148/radiol.2020201473
– volume: 345
  start-page: 113837
  year: 2021
  ident: CR35
  article-title: ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations
  publication-title: Exp. Neurol.
  doi: 10.1016/j.expneurol.2021.113837
– volume: 2
  start-page: e200213
  issue: 3
  year: 2020
  ident: CR23
  article-title: Investigators South-East Netherlands (CISEN) study group. Radiological society of North America Chest CT classification system for reporting COVID-19 pneumonia: Interobserver variability and correlation with reverse-transcription polymerase chain reaction
  publication-title: Radiol. Cardiothorac. Imaging.
  doi: 10.1148/ryct.2020200213
– volume: 8
  start-page: 206
  year: 2020
  ident: CR28
  article-title: COVID-19 infection and circulating ACE2 levels: Protective role in women and children
  publication-title: Front. Pead.
  doi: 10.3389/fped.2020.00206
– volume: 19
  start-page: 48
  issue: 1
  year: 2022
  ident: CR30
  article-title: SNPs of (rs4343) and (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease
  publication-title: Virol. J.
  doi: 10.1186/s12985-022-01782-6
– volume: 55
  start-page: 2001112
  issue: 5
  year: 2020
  ident: CR32
  article-title: Association between age and clinical characteristics and outcomes of COVID-19
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01112-2020
– volume: 31
  start-page: 165
  issue: 8
  year: 2021
  end-page: 171
  ident: CR16
  article-title: polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19
  publication-title: Pharmacogenet. Genomics.
  doi: 10.1097/FPC.0000000000000436
– volume: 142
  start-page: 106934
  year: 2022
  ident: CR39
  article-title: Assessment of ACE1 variants and ACE1/ACE2 expression in COVID-19 patients
  publication-title: Vascul. Pharmacol.
  doi: 10.1016/j.vph.2021.106934
– volume: 5
  start-page: 745
  issue: 7
  year: 2020
  end-page: 747
  ident: CR1
  article-title: Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers
  publication-title: JAMA Cardiol.
  doi: 10.1001/jamacardio.2020.1282
– volume: 64
  start-page: 386
  issue: 4
  year: 2021
  end-page: 399
  ident: CR13
  article-title: Epigenetic regulation of ACE2, the receptor of the SARS-CoV-2 virus
  publication-title: Genome.
  doi: 10.1139/gen-2020-0124
– volume: 19
  start-page: 48
  issue: 1
  year: 2022
  ident: CR15
  article-title: SNPs of (rs4343) and (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease
  publication-title: Virol. J.
  doi: 10.1186/s12985-022-01782-6
– volume: 24
  start-page: 422
  year: 2020
  ident: CR12
  article-title: Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
  publication-title: Crit. Care
  doi: 10.1186/s13054-020-03120-0
– volume: 11
  start-page: 753721
  year: 2021
  ident: CR40
  article-title: The impact of ACE2 polymorphisms on COVID-19 disease: Susceptibility, severity, and therapy
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2021
– volume: 186
  start-page: 906
  issue: 5
  year: 2023
  end-page: 922
  ident: CR27
  article-title: Angiotensin-converting enzyme 2 at the heart of the COVID-19 pandemic
  publication-title: Cell.
  doi: 10.1016/j.cell.2023.01.039
– volume: 43
  start-page: 219
  year: 2020
  end-page: 222
  ident: CR7
  article-title: Inhibitors of RAS might be a good choice for the therapy of COVID-19 Pneumonia
  publication-title: Zhonghua Jie He He Hu Xi Za Zhi
  doi: 10.3760/cma.j.issn.1001-0939.2020.03.016
– volume: 87
  start-page: e1
  year: 2000
  end-page: e9
  ident: CR2
  article-title: A novel angiotensin-converting enzyme related carboxypeptidase. (ACE2) converts angiotensin I to angiotensin 1e9
  publication-title: Circ. Res.
  doi: 10.1161/01.res.87.5.e1
– year: 2023
  ident: CR31
  article-title: The relationship between the clinical course of SARS-CoV-2 infections and ACE2 and TMPRSS2 expression and polymorphisms
  publication-title: Adv. Clin. Exp. Med.
  doi: 10.17219/acem/163409
– volume: 510
  start-page: 475
  year: 2020
  end-page: 482
  ident: CR33
  article-title: Laboratory findings in COVID-19 diagnosis and prognosis
  publication-title: Clin. Chim. Acta.
  doi: 10.1016/j.cca.2020.08.019
– volume: 256
  start-page: 117905
  year: 2020
  ident: CR3
  article-title: Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: Therapeutic implications
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.117905
– volume: 22
  start-page: 100979
  year: 2021
  ident: CR19
  article-title: Comprehensive in silico identification of impacts of SNPs on COVID-19 susceptibility in different populations
  publication-title: Gene Rep.
  doi: 10.1016/j.genrep.2020.100979
– year: 2004
  ident: CR44
  publication-title: Research Methodology: Methods and Techniques
– volume: 21
  start-page: 3474
  issue: 10
  year: 2020
  ident: 56260_CR17
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21103474
– volume: 11
  start-page: 741
  issue: 7
  year: 2020
  ident: 56260_CR36
  publication-title: Genes
  doi: 10.3390/genes11070741
– volume: 5
  start-page: 745
  issue: 7
  year: 2020
  ident: 56260_CR1
  publication-title: JAMA Cardiol.
  doi: 10.1001/jamacardio.2020.1282
– volume: 13
  start-page: 67
  issue: 1
  year: 2021
  ident: 56260_CR26
  publication-title: Viruses
  doi: 10.3390/v13010067
– volume: 14
  start-page: 1451
  issue: 7
  year: 2022
  ident: 56260_CR21
  publication-title: Viruses.
  doi: 10.3390/v14071451
– volume: 510
  start-page: 475
  year: 2020
  ident: 56260_CR33
  publication-title: Clin. Chim. Acta.
  doi: 10.1016/j.cca.2020.08.019
– year: 2023
  ident: 56260_CR31
  publication-title: Adv. Clin. Exp. Med.
  doi: 10.17219/acem/163409
– volume: 16
  start-page: e0252799
  issue: 6
  year: 2021
  ident: 56260_CR38
  publication-title: PLoS ONE.
  doi: 10.1371/journal.pone.0252799
– volume: 31
  start-page: 165
  issue: 8
  year: 2021
  ident: 56260_CR42
  publication-title: Pharmacogenet. Genom.
  doi: 10.1097/FPC.0000000000000436
– volume: 76
  start-page: 14
  year: 2020
  ident: 56260_CR11
  publication-title: Eur. J. Intern. Med.
  doi: 10.1016/j.ejim.2020.04.037
– volume: 31
  start-page: 165
  issue: 8
  year: 2021
  ident: 56260_CR16
  publication-title: Pharmacogenet. Genomics.
  doi: 10.1097/FPC.0000000000000436
– volume: 19
  start-page: 48
  issue: 1
  year: 2022
  ident: 56260_CR30
  publication-title: Virol. J.
  doi: 10.1186/s12985-022-01782-6
– volume: 157
  start-page: 104833
  year: 2020
  ident: 56260_CR4
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2020.104833
– volume: 6
  start-page: 317
  year: 2020
  ident: 56260_CR10
  publication-title: Eur. Heart J. Cardiovasc. Pharmacother.
  doi: 10.1093/ehjcvp/pvaa053
– volume: 9
  start-page: 2407
  issue: 14
  year: 2021
  ident: 56260_CR24
  publication-title: Int. J. Gen. Med.
  doi: 10.2147/IJGM.S310577
– volume: 8
  start-page: 206
  year: 2020
  ident: 56260_CR28
  publication-title: Front. Pead.
  doi: 10.3389/fped.2020.00206
– volume: 8
  start-page: e1344
  year: 2020
  ident: 56260_CR20
  publication-title: Mol. Genet. Genom. Med.
  doi: 10.1002/mgg3.1344
– volume: 87
  start-page: e1
  year: 2000
  ident: 56260_CR2
  publication-title: Circ. Res.
  doi: 10.1161/01.res.87.5.e1
– volume: 64
  start-page: 386
  issue: 4
  year: 2021
  ident: 56260_CR13
  publication-title: Genome.
  doi: 10.1139/gen-2020-0124
– volume: 53
  start-page: 425
  issue: 3
  year: 2020
  ident: 56260_CR14
  publication-title: J. Microbiol. Immunol. Infect.
  doi: 10.1016/j.jmii.2020.04.015
– volume: 345
  start-page: 113837
  year: 2021
  ident: 56260_CR35
  publication-title: Exp. Neurol.
  doi: 10.1016/j.expneurol.2021.113837
– volume-title: Research Methodology: Methods and Techniques
  year: 2004
  ident: 56260_CR44
– volume: 55
  start-page: 2001112
  issue: 5
  year: 2020
  ident: 56260_CR32
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.01112-2020
– volume: 142
  start-page: 106934
  year: 2022
  ident: 56260_CR39
  publication-title: Vascul. Pharmacol.
  doi: 10.1016/j.vph.2021.106934
– volume: 11
  start-page: 1098
  issue: 11
  year: 2021
  ident: 56260_CR43
  publication-title: J. Pers. Med.
  doi: 10.3390/jpm11111098
– volume: 762
  start-page: 145102
  year: 2020
  ident: 56260_CR41
  publication-title: Gene
  doi: 10.1016/j.gene.2020.145102
– volume: 2
  start-page: e200213
  issue: 3
  year: 2020
  ident: 56260_CR23
  publication-title: Radiol. Cardiothorac. Imaging.
  doi: 10.1148/ryct.2020200213
– volume: 19
  start-page: e13168
  issue: 7
  year: 2020
  ident: 56260_CR37
  publication-title: Aging Cell.
  doi: 10.1111/acel.13168
– volume: 19
  start-page: 48
  issue: 1
  year: 2022
  ident: 56260_CR15
  publication-title: Virol. J.
  doi: 10.1186/s12985-022-01782-6
– volume: 7
  start-page: 563893
  year: 2021
  ident: 56260_CR34
  publication-title: Front Med
  doi: 10.3389/fmed.2020.563893
– volume: 17
  start-page: 3433
  issue: 10
  year: 2020
  ident: 56260_CR18
  publication-title: Int. J. Environ. Res. Public Health.
  doi: 10.3390/ijerph17103433
– volume: 11
  start-page: 753721
  year: 2021
  ident: 56260_CR40
  publication-title: Front. Cell Infect. Microbiol.
  doi: 10.3389/fcimb.2021
– volume: 20
  start-page: 407
  year: 2020
  ident: 56260_CR6
  publication-title: Infect. Disord. Drug Targets.
  doi: 10.2174/1871526520666200518073329
– volume: 43
  start-page: 219
  year: 2020
  ident: 56260_CR7
  publication-title: Zhonghua Jie He He Hu Xi Za Zhi
  doi: 10.3760/cma.j.issn.1001-0939.2020.03.016
– volume: 22
  start-page: 100979
  year: 2021
  ident: 56260_CR19
  publication-title: Gene Rep.
  doi: 10.1016/j.genrep.2020.100979
– volume: 256
  start-page: 117905
  year: 2020
  ident: 56260_CR3
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.117905
– volume: 24
  start-page: 422
  year: 2020
  ident: 56260_CR12
  publication-title: Crit. Care
  doi: 10.1186/s13054-020-03120-0
– volume: 7
  start-page: 335
  year: 2020
  ident: 56260_CR5
  publication-title: Front. Med.
  doi: 10.3389/fmed.2020.00335
– volume: 186
  start-page: 906
  issue: 5
  year: 2023
  ident: 56260_CR27
  publication-title: Cell.
  doi: 10.1016/j.cell.2023.01.039
– volume: 8
  start-page: 206
  year: 2020
  ident: 56260_CR8
  publication-title: Front. Pediatr.
  doi: 10.3389/fped.2020.00206
– volume: 81
  start-page: 537
  year: 2020
  ident: 56260_CR9
  publication-title: Drug Dev. Res.
  doi: 10.1002/ddr.21656
– volume: 296
  start-page: E97
  issue: 2
  year: 2020
  ident: 56260_CR22
  publication-title: Radiology.
  doi: 10.1148/radiol.2020201473
– volume: 395
  start-page: 507
  year: 2020
  ident: 56260_CR29
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 13
  start-page: 888025
  year: 2020
  ident: 56260_CR25
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2022.888025
SSID ssj0000529419
Score 2.4127073
Snippet The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for SARS-CoV-2...
Abstract The expression of ACE2 is linked to disease severity in COVID-19 patients. The ACE2 receptor gene polymorphisms are considered determinants for...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 5846
SubjectTerms 631/250
631/326
631/337
631/45
ACE2
Alleles
Angiotensin-converting enzyme 2
COVID-19
Diabetes mellitus
Disease control
Enzyme-linked immunosorbent assay
Gene polymorphism
Genetic diversity
Genetic variance
Genotype & phenotype
Genotypes
Humanities and Social Sciences
Hypertension
Infections
multidisciplinary
Polymorphism
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yIHgR12e7q0TwpmG78-hJvK3jLKvgA3RlbyHpVOOA27M4Mwf_vVVJz7jjAy9eO6Epqr7qqnRVvmLsae26Sa11EiYpKXQDjQitroUJfTdBDDib2fnfvmtPz_Sbc3N-ZdQX9YQVeuCiuKM0iRq_tFRQirptZdQ9vpwoSwxI6BN9fTHmXTlMFVZv6XTjxlsytbJHS4xUdJtMamEoiRftTiTKhP1_yjJ_b5b8pWKaA9HJLXZzzCD5cZF8n12D4Ta7XmZKfr_D1uj96wt-PJ1JHobEPzbuA0eUAL9cfMWDPup1vrzg84HPaAIZooOP3KpLTj9l-fT959evROP4pk9reME7muFRuubKprGuwzGuAo2_u8vOTmafpqdinK0gOu3kSoCuk-z7HtCjwUJdJwgB3dFFi_l2MMZAUlqBIkZ600dLrC2hqwPYSQxOqXtsb1gM8IBxm4KxtosKMLkyYEMHMQaNxlFO1RIq9myjZ39ZKDR8Ln0r64tVPFrFZ6v4tmIvyRTbnUR_nR8gKPwICv8vUFTscGNIP_rk0lNFszXUgFqxJ9tl9CYqkYQBFuu8p_DfmIrdL3bfSqIwVcN0RlbM7iBiR9TdlWH-JTN2I-bx6GZtxZ5vwPNTrr_r4uH_0MUBuyEJ9bkH8ZDtrb6t4REmUqv4OPvMD2UNFyg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELbGEBJfEO9kDGQkvoEh8UtiIyE0SqeBNECCon2z7OQClbZ064vE_j1nOykqFL7Grur4nus97p2fI-Rpbuoql7JhqhGcyQIK5kqZM-XaukIMGB3V-Y8_lkcT-eFEneyQod1Rv4GLrUe70E9qMj998fPi8g06_Ot0ZVy_XGAQChfFuGQq8HNWXiFXMTJVwVGPe7qftL65kYXp785s_-hGfIoy_tu4598llH_kUWN4OrxJbvS8kh4kINwiO9DdJtdSp8nLO2SFvwmrM3owGnPquoZ-KcxnitgBej47xeM_7vZ0cUanHR2HvmSIGdorri5o-KuWjj59e_-OFYYO1VvdK1qHzh6pli5N6rM9FKMthKZ4d8nkcPx1dMT6jgusloYvGci84W3bAvo5aMjzBpxDJzVeIwt3SilohBQggk69ar0OWi6uzh3oyjsjxD2y2806eECobpzSuvYCkHIp0K4G753k0Aojcg4ZeTbssz1Pwho2JsSFtskqFq1io1VsmZG3wRTrmUEUOz6Yzb_b3sdsU3mJQTnkHr0sS-5lizgM6jYK8HubjOwPhrQD0GzIc5YqlKVm5Ml6GH0sJE5cB7NVnJNUcVRG7ie7r1cikMAhyeEZ0RuI2Fjq5kg3_RF1vNET8ECndUaeD-D5va5_78Xe_1_jIbnOA55jzeE-2V3OV_AIidPSP47e8AsyHhLM
  priority: 102
  providerName: Scholars Portal
– databaseName: SpringerOpen Free (Free internet resource, activated by CARLI)
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9QwDLaWRUhcEG8KCwoSN4ho8-ik3JYyqwWJhwSL9hYlrQsjsZ3VzsyBf4-dtoMGlgPXJlWt-HPtxM5ngGd51cxyY1ppW62kKbCQoTS5tKFrZoSByiV2_vcfyuMT8-7Unu6Bmu7CpKL9RGmZftNTddjLFTkavgymjLQcg8vyClxl6nZGdV3W23MVzlyZohrvx-TaXfLqjg9KVP2XxZd_l0n-kStNLujoJtwYY0dxOEh7C_awvw3Xhm6SP-_Ahux-cyYO67kSoW_F56L6JAgfKM6XP2iLTyu6WJ2JRS_m3HuMcCFGVtWV4ONYUX_8-vaNLCoxVWj1r0TD3TuGerlh0pjREeRRkRvf3YWTo_mX-liOXRVkYyq1lmjyVnVdh2TL6DDPWwyBDLGKjiLtYK3FVhuNmrnobRcd87WEJg_oZjFUWt-D_X7Z4wMQrg3WuSZqpLDKogsNxhiMwk5XOleYwfNpnf35QJ7hU9JbOz9oxZNWfNKKLzN4zarYzmTi6_RgefHNj0Dw7SwacrycX4ymLFU0HWGNGWws0nfbDA4mRfrRGleec5ml5dLTDJ5uh8mOODkSelxu0pyB-cZmcH_Q-1YSTUEaBTIqA7eDiB1Rd0f6xffE1U1op02bcxm8mMDzW65_r8XD_5v-CK4rxneqMzyA_fXFBh9TsLSOT5J1_AInxQ1v
  priority: 102
  providerName: Springer Nature
Title Serum ACE2 and S19P gene polymorphism in Egyptian patients with COVID-19 infection: correlation with disease severity
URI https://link.springer.com/article/10.1038/s41598-024-56260-6
https://www.ncbi.nlm.nih.gov/pubmed/38462662
https://www.proquest.com/docview/2954651074
https://www.proquest.com/docview/2955268405
https://pubmed.ncbi.nlm.nih.gov/PMC10925588
https://doaj.org/article/d7b43410739b4662b4f70496585e2efd
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIvaHwubFRG4g2spbGdOLygLnQalTYmxlDfLCe5QCWWlKV94L_nzkk6la-XREosxfH9zne5u_yOsVdhWiShUqXQpYyEGsNYuFiFQruqSBADqfHs_Gfn8emVms31vA-4tX1Z5bAn-o26bAqKkR9RPirWVD74bvlDUNcoyq72LTTusl2iLqOSrmSebGIslMVS47T_VyaU5qhFe0X_lEVKaHLlRbxljzxt_998zT9LJn_Lm3pzdLLHHvR-JJ90gn_I7kD9iN3rOkv-fMzWuAesr_kkm0bc1SW_HKcXHLECfNl8x899XN1Fe80XNZ9SHzLECO8ZVltOoVmeffzy4b0Yp3yo1qrf8oI6eXS1c92gPrvD0boCNcF7wq5Opp-zU9F3WBCFSqOVABWWUVVVgHoNBsKwBOdQKdPcoNfttNZQSiVBEi-9rnJD3C2uCB2YJHeplE_ZTt3UsM-4KZ02psgloIulwbgC8typCCqZyjCCgL0e1tkuOyIN6xPg0thOKhalYr1UbBywYxLFZiSRYPsLzc1X2-uULZNcoRGmXGOu4jjKVYW4IzYbDfjcMmCHgyBtr5mtvcVRwF5ubqNOUaLE1dCs_ZiOBUcH7Fkn981MJDps6NREATNbiNia6vadevHN83Yj8vEDzpiAvRnAczuvf6_F8_-_xgG7HxGefY3hIdtZ3azhBTpKq3zktWHEdieT2eUMz8fT84tPeDWLs5EPPuDxTJlfLcsVbw
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEB5VqRC8IG4MBRYJnsCqvYezRkKoTVMltA0VtFXflrW9hkjEDk0ilD_Fb2TGR6pwvfXVXsnrnW-O3Zn9BuBFEKfdQMrMV5ngvgxd6NtIBr6yedpFDMS6Yuc_GkWDU_n-XJ1vwM_2LgyVVbY2sTLUWZnSGfk25aMiReWD76bffeoaRdnVtoVGDYsDt_yBW7bZ2-Eeyvcl5_v9k97Ab7oK-KmM-dx3Msh4nucOsey0C4LMWYtAjBONkaZVSrlMSOEEcbGrPNHEV2LTwDrdTWxMB6Bo8jelwK1MBzZ3-6Pjj6tTHcqbyTBubucEQm_P0EPSLTYufUWbBz9a84BVo4C_Rbd_Fmn-lqmtHOD-LbjZRK5sp4babdhwxR24VveyXN6FBVqdxYTt9Pqc2SJjn8L4mCE6HZuW35aTEuU5nk3YuGB96nyGqGQNp-uM0WEw6304G-75Ycza-rDiDUupd0hdrVcPavJJDP25o7Z79-D0Slb_PnSKsnAPgenMKq3TRDgM6pTTNnVJYiV3uYhFwJ0Hr9p1NtOausNUKXehTS0Vg1IxlVRM5MEuiWI1kmi3qwflxRfTaLHJuolEt0_ZzURGEU9kjkgn_hzl8LuZB1utIE1jC2bmErkePF-9Ri2m1IwtXLmoxtS8O8qDB7XcVzMRGCJiGMU90GuIWJvq-pti_LViCkddwy2j1h68bsFzOa9_r8Wj___GM7g-ODk6NIfD0cFjuMEJ21WF4xZ05hcL9wTDtHnytNENBp-vWh1_Acz2Tgw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIRAviDuBAUaCJ7Ca-JI4SAiNXrQyGJNgqG-ekzhQiSZlbYX61_h1nOMkncrtba-JpTg-37nY5_g7hDwN0zwJpSyYKgRnMnIRs7EMmbJlngAGUu3Z-d8fxQcn8u1ETXbIz-4uDJZVdjbRG-qizvGMvIf5qFhh-WCvbMsijgej1_PvDDtIYaa1a6fRQOTQrX_A9m3xajwAWT_jfDT81D9gbYcBlsuUL5mTYcHLsnSAa6ddGBbOWgBlmmmIOq1SyhVCCieQl12VmUbuEpuH1ukksykehoL5v5QIFaGOJZNkc76DGTQZpe09nVDo3gJ8Jd5n45Ip3EaweMsX-pYBf4tz_yzX_C1n613h6Dq51sawdL8B3Q2y46qb5HLT1XJ9i6zA_qxmdL8_5NRWBf0YpccUcOrovP62ntUg2eliRqcVHWIPNMAnbdldFxSPhWn_w-fxgEUp7SrFqpc0xy4iTd1eM6jNLFHw7A4b8N0mJxey9nfIblVX7h6hurBK6zwTDsI75bTNXZZZyV0pUhFyF5Dn3TqbeUPiYXzyXWjTSMWAVIyXiokD8gZFsRmJBNz-QX32xbT6bIokkxAAYJ4zk3HMM1kC5pFJRzn4bhGQvU6QprUKC3OO4YA82bwGfcYkja1cvfJjGgYeFZC7jdw3MxEQLEJAxQOitxCxNdXtN9X0q-cMB62DzaPWAXnRged8Xv9ei_v__43H5AoooXk3Pjp8QK5yhLYvddwju8uzlXsI8doye-QVg5LTi9bEX7CWUNw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+ACE2+and+S19P+gene+polymorphism+in+Egyptian+patients+with+COVID-19+infection%3A+correlation+with+disease+severity&rft.jtitle=Scientific+reports&rft.au=Gaber%2C+Dalia+A&rft.au=Shokr%2C+Mohamed&rft.au=Shaker%2C+Olfat&rft.au=Zaki%2C+Kamelia+Ahmed&rft.date=2024-03-10&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft.spage=5846&rft_id=info:doi/10.1038%2Fs41598-024-56260-6&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon